MetaCap

Aardvark Therapeutics (AARD) vs Marker Therapeutics (MRKR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Marker Therapeutics (MRKR) has outperformed Aardvark Therapeutics (AARD) over the past year, gaining 2.8% versus a loss of 90.2%. Aardvark Therapeutics is the larger company by market cap ($20.2 million vs $18.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AARD-90.15%MRKR+2.83%
+116%+8%-100%
Nov 21, 20251 yearNov 20, 2026
AARD-93.06%MRKR-36.63%
+28%-35%-99%
Feb 10, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AARD versus MRKR key metrics
MetricAARDMRKR
Share price$0.9226$1.09
Market cap$20.20M$18.17M
1-day change-7.74%-17.42%
YTD return-92.97%-26.85%
1-year return-90.15%+2.83%
5-year return—-91.14%
EPS (TTM)$-3.33$-0.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$3.55M
Revenue growth (YoY)—-46.19%
Net income (latest FY)$-57.59M$-12.16M
Operating margin—-363.45%
Net margin—-342.96%
52-week high$16.60$2.46
52-week low$0.90$0.81
Distance from 52-week high-94.44%-55.69%
Analyst consensusbuynone
Avg. price target upside+1104.21%+622.02%
Average volume643.53K711.96K
Shares outstanding21.89M16.67M
Employees285
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRKR has outperformed AARD by 93.0 percentage points over the past year.

About Aardvark Therapeutics

AARD stock →

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Marker Therapeutics

MRKR stock →

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

AARD vs MRKR FAQ

Which is bigger, Aardvark Therapeutics or Marker Therapeutics?

Aardvark Therapeutics (AARD) is larger, with a market capitalization of $20.20M compared with $18.17M for Marker Therapeutics (MRKR).

Which stock has performed better over the past year, AARD or MRKR?

MRKR returned +2.83% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.

Are Aardvark Therapeutics and Marker Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons